JP2004525906A - アリールｎ−シアノグアニジンおよびこれに関連する方法 - Google Patents

アリールｎ−シアノグアニジンおよびこれに関連する方法 Download PDF

Info

Publication number
JP2004525906A
JP2004525906A JP2002567895A JP2002567895A JP2004525906A JP 2004525906 A JP2004525906 A JP 2004525906A JP 2002567895 A JP2002567895 A JP 2002567895A JP 2002567895 A JP2002567895 A JP 2002567895A JP 2004525906 A JP2004525906 A JP 2004525906A
Authority
JP
Japan
Prior art keywords
mitochondrial
cell
cells
compound according
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525906A5 (enExample
Inventor
サウミトラ エス． ゴッシュ，
トマス アール． スザボ，
Original Assignee
マイトコー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マイトコー filed Critical マイトコー
Publication of JP2004525906A publication Critical patent/JP2004525906A/ja
Publication of JP2004525906A5 publication Critical patent/JP2004525906A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
JP2002567895A 2001-02-27 2002-02-27 アリールｎ−シアノグアニジンおよびこれに関連する方法 Pending JP2004525906A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27236801P 2001-02-27 2001-02-27
PCT/US2002/006717 WO2002068381A2 (en) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto

Publications (2)

Publication Number Publication Date
JP2004525906A true JP2004525906A (ja) 2004-08-26
JP2004525906A5 JP2004525906A5 (enExample) 2005-12-22

Family

ID=23039505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567895A Pending JP2004525906A (ja) 2001-02-27 2002-02-27 アリールｎ−シアノグアニジンおよびこれに関連する方法

Country Status (9)

Country Link
US (4) US6562821B2 (enExample)
EP (1) EP1377282B1 (enExample)
JP (1) JP2004525906A (enExample)
AT (1) ATE336237T1 (enExample)
AU (1) AU2002254124A1 (enExample)
CA (1) CA2475454A1 (enExample)
DE (1) DE60213958T2 (enExample)
ES (1) ES2271247T3 (enExample)
WO (1) WO2002068381A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562821B2 (en) * 2001-02-27 2003-05-13 Mitokor Aryl-N-cyanoguanidines and methods related thereto
US7411000B2 (en) * 2001-03-15 2008-08-12 The Scripps Research Institute Process of inhibiting cell death in injured cartilage
WO2003050261A2 (en) * 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
US7642092B2 (en) * 2003-03-03 2010-01-05 Technion Research & Development Foundation Ltd. Cultured cartilage/bone cells/tissue, method of generating same and uses thereof
US20210052659A1 (en) * 2018-02-02 2021-02-25 Paean Biotechnology Inc. Pharmaceutical composition comprising isolated mitochondria for prevention or treatment of rheumatoid arthritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265905A (en) * 1975-09-30 1981-05-05 Merck & Co., Inc. Method of treating inflammation employing acyl cyanoguanidines
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
KR20020084273A (ko) * 2000-03-31 2002-11-04 화이자 프로덕츠 인코포레이티드 신규한 피페라진 유도체
US6562821B2 (en) * 2001-02-27 2003-05-13 Mitokor Aryl-N-cyanoguanidines and methods related thereto

Also Published As

Publication number Publication date
AU2002254124A1 (en) 2002-09-12
EP1377282A2 (en) 2004-01-07
DE60213958T2 (de) 2007-08-30
ATE336237T1 (de) 2006-09-15
US7230132B2 (en) 2007-06-12
US20030045556A1 (en) 2003-03-06
ES2271247T3 (es) 2007-04-16
US6562821B2 (en) 2003-05-13
US20080032981A1 (en) 2008-02-07
US6927218B2 (en) 2005-08-09
EP1377282B1 (en) 2006-08-16
CA2475454A1 (en) 2002-09-06
US20040067987A1 (en) 2004-04-08
US20050182057A1 (en) 2005-08-18
WO2002068381A3 (en) 2002-10-31
DE60213958D1 (de) 2006-09-28
WO2002068381A2 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
US6268398B1 (en) Compounds and methods for treating mitochondria-associated diseases
KR0178543B1 (ko) N,n'-이치환된 구아니딘과 흥분유발 아미노산 길항제로서 그 사용방법
CN100435785C (zh) 抑制iapp的化合物或其可药用酯或其可药用盐的制药应用
MXPA04001153A (es) Derivados de amidina para tratar la amiloidosis.
JP2003113184A (ja) ビス−スタウロスポリンおよびＫ−２５２ａ誘導体
TW200530163A (en) 2-substituted and 4-substituted aryl nitrone compounds
US6593362B2 (en) Non-peptidic cyclophilin binding compounds and their use
US20080032981A1 (en) Aryl n-cyanoguanidines and methods related thereto
MXPA02011160A (es) Inhibidores del transporte de fosfato.
US20100069619A1 (en) Stilbene derivatives for adp-ribosyl cyclase inhibitors
CA2488493A1 (en) Amidine derivatives for treating amyloidosis
WO2000003704A1 (en) Macrophage scavenger receptor antagonists
US9463195B2 (en) Dissolution of amyloid fibrils by flavonoids and other compounds
EP1366021B1 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
US6251898B1 (en) Medical use of fluorenone derivatives for treating and preventing brain and spinal injury
JP2004099560A (ja) 薬剤性腎障害の予防及び／又は治療のための医薬
JP2756941B2 (ja) ２−クロロ−３−アリールアミノ−１，４−ナフトキノン誘導体の血小板凝集抑制剤としての用途
US5869526A (en) δ-(S-methylisothioureido)-L-norvaline therapeutic for cerebrovascular diseases having nitric oxide synthase inhibiting factor
WO2001014334A1 (en) Fluorenone compounds with modified 7-position substituents for treating and preventing brain and spinal injury
AU2002325117A1 (en) Amidine derivatives for treating amyloidosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090331